Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.38 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.37 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.37 |
| ▸ | NT5E | P21589 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12929186 | 0.90 | ABL1 (0.39) | ABL1RIN1P2RY6P2RY14NT5E | |
| SCHEMBL12636445 | 0.89 | ABL1 (0.38) | ABL1RIN1P2RY6P2RY14NT5E | |
| SCHEMBL12929179 | 0.89 | ABL1 (0.38) | ABL1RIN1P2RY6P2RY14NT5E | |
| SCHEMBL12636396 | 0.83 | P2RY6 (0.46) | ABL1RIN1P2RY6P2RY14NT5E | |
| SCHEMBL12636311 | 0.81 | ABL1 (0.35) | ABL1RIN1P2RY6P2RY14NT5E | |
| SCHEMBL12636314 | 0.75 | P2RY6 (0.44) | ABL1RIN1P2RY6P2RY14NT5E | |
| SCHEMBL12636350 | 0.73 | P2RY6 (0.48) | ABL1RIN1P2RY6P2RY14NT5E | |
| SCHEMBL12306533 | 0.73 | ABL1 (0.43) | ABL1RIN1P2RY6P2RY14NT5E | |
| SCHEMBL12306549 | 0.73 | ABL1 (0.43) | ABL1RIN1P2RY6P2RY14NT5E | |
| SCHEMBL12929180 | 0.73 | P2RY6 (0.46) | ABL1RIN1P2RY6P2RY14NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7939677-B2 | Oligomeric compounds comprising 4′-thionucleosides for use in gene modulation | ISIS PHARMACEUTICALS, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-7875733-B2 | Nucleosides; RNA interference; gene expression inhibition; for use in therapeutic, diagnostic, and research applications involving gene silencing | ISIS PHARMACEUTICALS, INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-20100324277-A1 | OLIGOMERIC COMPOUNDS COMPRISING 4'-THIONUCLEOSIDES FOR USE IN GENE MODULATION | ISIS PHARMACEUTICALS, INC. (US) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324277-A1 | OLIGOMERIC COMPOUNDS COMPRISING 4'-THIONUCLEOSIDES FOR USE IN GENE MODULATION | SNRPE, NSUN3, NSUN2 | ABL1 4626/4885RIN1 1264/4885P2RY6 4305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.